GENVEC- WKN 580662 suche infos - 500 Beiträge pro Seite

[gs231]

bitte teilt mir eure infos über GENVEC Wkn 580662 mit !
Danke.

[schakal23]

10.03.2005 21:56:
GenVec to Present at SQ Cowen & Co. 25th Annual Healthcare Conference


GAITHERSBURG, Md., March 10 /PRNewswire-FirstCall/ -- GenVec (Nachrichten) today announced that the Company`s President and CEO, Paul H. Fischer, Ph.D., will present a corporate update at the SG Cowen & Co. 25th Annual Healthcare Conference, which is being held at the Marriott Copley Place Hotel in Boston, on Wednesday, March 16, 2005 at 10:30 am Eastern Standard Time. The presentation will be webcast live and the replay will become available approximately one hour following the live webcast. To access the webcast, please visit GenVec`s website at http://www.genvec.com/ and click on Webcasts & Data.

GenVec is a clinical stage biopharmaceutical company developing treatments for cancer, heart disease, vision loss, and vaccines for infectious diseases. GenVec`s product candidates in clinical development include TNFerade(TM) for locally advanced pancreatic cancer, BIOBYPASS(R) for severe coronary artery disease, and AdPEDF for wet age-related macular degeneration. Additional information on GenVec is available at http://www.genvec.com/ and in GenVec`s various filings with the Securities and Exchange Commission.


da könnte was posetives berichtet werden

[schakal23]

GenVec Reports First Quarter 2005 Financial Results
GenVec Reports First Quarter 2005 Financial Results



BW5784 APR 27,2005 13:00 PACIFIC 16:00 EASTERN



( BW)(MD-GENVEC)(GNVC) GenVec Reports First Quarter 2005 FinancialResults

Business Editors/Biotech Writers
BIOWIRE2K

GAITHERSBURG, Md.--(BUSINESS WIRE)--April 27, 2005--GenVec, Inc.(Nasdaq:GNVC), today announced its financial results for the firstquarter ended March 31, 2005. GenVec reported a net loss of $3.5million ($0.06 per share) compared to a net loss of $5.6 million($0.11 per share) in the comparable quarter of 2004. The net lossimprovement was primarily due to the increase in revenues fromgovernment-funded programs supporting the development of HIV andmalaria vaccines. GenVec ended the first quarter of 2005 with $28.0million in cash and investments.
Revenue for the first quarter increased to $4.5 million from $2.7million for the same period last year. Revenue was derived primarilyfrom the Company´s funded research and development programs with theNational Institutes of Health (NIH), the United States Naval MedicalResearch Center and PATH´s Malaria Vaccine Initiative, all of whichuse GenVec´s proprietary technology for the development of clinicalgrade vaccine candidates, and our collaboration with FusoPharmaceutical Industries for the development of a targeted cancertherapy. The 67 percent increase in revenue for the first quarter of2005 was primarily due to a $10 million expansion of the Company´s HIVvaccine development program with the NIH. This program now extendsthrough 2008 and will provide up to $40 million in research anddevelopment payments to GenVec.
Operating expenses for the first quarter of 2005 decreased 4percent, to $8.1 million from $8.4 million in the first quarter of2004, primarily due to lower levels of license fee payments andoutside costs related to the manufacture of clinical supplies for theCompany´s ongoing TNFerade development program.

First Quarter 2005 Highlights



--
Initiation of a 74 patient randomized, controlled Phase II clinical trial of TNFerade(TM) in patients with locally advanced pancreatic cancer.

--
Initiation of a 129 patient randomized, placebo-controlled Phase II clinical trial of BIOBYPASS(R) in patients with severe coronary artery disease under a research collaboration with Cordis Corporation, a Johnson & Johnson company. BIOBYPASS will be administered directly into targeted regions of the heart using the Cordis NOGASTAR(R) Mapping and MYOSTAR(TM) Injection Catheter System.

--
Initiation of an expanded Phase I trial of AdPEDF in patients with recently diagnosed wet age-related macular degeneration, the leading cause of blindness in people over the age of 50.

--
Presentation of Phase I clinical data from our HIV vaccine development program at the recent Keystone Symposium on HIV Vaccines demonstrating that the HIV vaccine was well tolerated and produced both cellular and antibody responses at each dose level tested.

--
Presentation of preclinical data at the American Association of Cancer Research Meeting showing that TNFerade significantly reduced the spread (metastasis) of cancer to lymph nodes in a mouse model of melanoma cancer. We also reported the successful targeting and efficacious treatment in a mouse model of ovarian cancer using a next generation targeted vector to deliver the tumor necrosis factor-alpha gene. GenVec´s work with targeted vectors is being funded in part by our multi-year research collaboration with Fuso Pharmaceutical Industries of Japan.

"Our financial performance during the first quarter of 2005reflected prudent management of our resources, continued clinicalprogress with all of our product candidates including the resumptionof TNFerade clinical testing, and the success of our vaccinedevelopment programs," said Jeffrey W. Church, GenVec´s chieffinancial officer. "We continue to expect revenues from collaboratorsof approximately $18 and $20 million this year, which will help offsetthe costs of our expanding clinical development programs."

Conference Call Information

GenVec will host its quarterly conference call at 4:30 p.m.Eastern time (1:30 p.m. Pacific time) today. The conference call willbe accessible via GenVec´s website at www.genvec.com under Webcasts &Data or by telephone at 800-688-0836 (U.S. or Canada) or 617-614-4072(international); access code 14380515. An archive of the conferencecall will be available on GenVec´s website approximately one hourafter the event for 30 days.

GenVec is a clinical-stage biopharmaceutical company developinginnovative gene-based therapeutics to treat cancer, heart disease, andophthalmic disorders. Each of our gene-based product candidates uses acommon patent-protected platform to deliver genes that producemedically beneficial proteins directly at the site of disease -TNFerade(TM) for oncology, BIOBYPASS(R) for cardiovascular disease,and PEDF for ophthalmology. Additional information on GenVec isavailable at its website at www.genvec.com and in the Company´svarious filings with the Securities and Exchange Commission.

Statements herein relating to future financial or businessperformance, conditions or strategies and other financial and businessmatters, including expectations regarding future revenues andoperating expenses, are forward-looking statements within the meaningof the Private Securities Litigation Reform Act. GenVec cautions thatthese forward-looking statements are subject to numerous assumptions,risks and uncertainties, which change over time. Factors that maycause actual results to differ materially from the results discussedin the forward-looking statements or historical experience includerisks and uncertainties, including the failure by GenVec to secure andmaintain relationships with collaborators; risks relating to the earlystage of GenVec´s product candidates under development; uncertaintiesrelating to clinical trials; risks relating to the commercialization,if any, of GenVec´s proposed product candidates; dependence on theefforts of third parties; dependence on intellectual property; andrisks that we may lack the financial resources and access to capitalto fund our operations. Further information on the factors and risksthat could affect GenVec´s business, financial conditions and resultsof operations, are contained in GenVec´s filings with the U.S.Securities and Exchange Commission (SEC), which are available atwww.sec.gov. These forward-looking statements speak only as of thedate of this press release, and GenVec assumes no duty to updateforward-looking statements.

GenVec, Inc. Condensed Statements of Operations (in thousands, except per share data) Three Months Ended March 31, --------------------- 2005 2004 ---------- ---------- (Unaudited) ---------------------Revenue from strategic alliances and research contracts $4,549 $2,741 ---------- ----------Operating expenses: Research and development 5,906 6,321 General and administrative 2,198 2,096 Total operating expenses 8,104 8,417 ---------- ----------Loss from operations (3,555) (5,676) Interest income 185 114 Interest expense (88) (88)Net loss $(3,458) $ (5,650) ========== ==========Basic and diluted loss per share $(0.06) $(0.11) ========== ==========Shares used in computing basic and diluted net loss per share 55,636 51,408 ========== ========== GenVec, Inc. Selected Balance Sheet Information (in thousands) March 31, December 31, 2005 2004 ------------ ------------- (Unaudited)Cash and investments $27,970 $33,065Working Capital 22,614 26,021Total assets 38,544 44,071Stockholder´s equity 27,109 30,481

--30--RB/ph* CONTACT: GenVec, Inc. Jeffrey W. Church, 240-632-5510 [e-mail] KEYWORD: MARYLAND DISTRICT OF COLUMBIA INDUSTRY KEYWORD: MEDICAL BANKING BIOTECHNOLOGY EARNINGSCONFERENCE CALLS SOURCE: GenVec, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

kann jemand was dazu sagen?

[rairai]

haltet ihr genvec jetzt für kaufenswert?

[schakal23]

ich denke schon

alle warten auf ein schups bei genvec und dann werd die rakete gestartet wenn da ein posetives meldung kommt und ich reschne mit einen das ist nur mein meinung

[rairai]

wann tut sich mal was bei diesem wert?

[celto]

Schönen Abend, 22.06.05:Kaufempfehlung von FERRIS BAKER zu Genvec,Kursziel wird von 4 auf 6 Dollar erhöht(Finanznachrichten.de),ciao celto